Table 2. EORTC QLQ-C30 questionnaire assessment in the QLQ-C30 set (N=245).
|
XELOX group, n=126
|
FOLFOX-6 group, n=119
|
||||||
|---|---|---|---|---|---|---|---|
| EORTC QLQ-C30 | n | MV (%) | Mean (s.d.) | n | MV (%) | Mean (s.d.) | *P-value |
| Physical functioning (%) | |||||||
| Baseline | 126 | 0.0 | 80.7 (20.2) | 118 | 0.8 | 79.1 (21.9) | 0.952 |
| C3/C4 | 98 | 0.0 | 80.5 (22.0) | 96 | 1.0 | 78.9 (19.0) | 0.225 |
| C6/C8 | 78 | 0.0 | 80.0 (18.5) | 72 | 2.7 | 79.5 (18.6) | 0.645 |
| Final visit | 63 | 0.0 | 75.9 (22.0) | 65 | 0.0 | 74.9 (21.0) | 0.631 |
| Role functioning (%) | |||||||
| Baseline | 124 | 1.6 | 71.2 (31.8) | 116 | 2.5 | 68.2 (32.3) | 0.484 |
| C3/C4 | 98 | 0.0 | 73.8 (28.7) | 96 | 1.0 | 67.4 (30.6) | 0.121 |
| C6/C8 | 78 | 0.0 | 74.8 (28.9) | 73 | 1.4 | 70.5 (27.0) | 0.198 |
| Final visit | 62 | 1.6 | 69.9 (32.1) | 65 | 0.0 | 65.1 (29.4) | 0.206 |
| Cognitive functioning (%) | |||||||
| Baseline | 123 | 2.4 | 83.7 (20.5) | 118 | 0.8 | 83.2 (22.2) | 0.961 |
| C3/C4 | 98 | 0.0 | 85.0 (19.9) | 96 | 1.0 | 82.3 (20.5) | 0.247 |
| C6/C8 | 78 | 0.0 | 79.3 (23.1) | 74 | 0.0 | 82.0 (19.3) | 0.641 |
| Final visit | 63 | 0.0 | 78.6 (19.3) | 64 | 1.5 | 77.7 (19.5) | 0.631 |
| Emotional functioning (%) | |||||||
| Baseline | 124 | 1.6 | 68.8 (25.2) | 117 | 1.7 | 68.0 (24.5) | 0.715 |
| C3/C4 | 98 | 0.0 | 78.6 (20.2) | 96 | 1.0 | 75.2 (22.0) | 0.333 |
| C6/C8 | 78 | 0.0 | 79.2 (20.4) | 74 | 0.0 | 75.6 (21.9) | 0.285 |
| Final visit | 62 | 1.6 | 72.7 (23.8) | 64 | 1.5 | 69.7 (24.2) | 0.438 |
| Social functioning (%) | |||||||
| Baseline | 123 | 2.4 | 77.2 (30.1) | 116 | 2.5 | 76.1 (27.6) | 0.461 |
| C3/C4 | 98 | 0.0 | 79.3 (24.8) | 96 | 1.0 | 72.9 (26.2) | 0.058 |
| C6/C8 | 78 | 0.0 | 78.8 (25.4) | 74 | 0.0 | 78.2 (25.3) | 0.924 |
| Final visit | 63 | 0.0 | 73.5 (28.7) | 64 | 1.5 | 71.6 (27.0) | 0.539 |
| Global quality of life scale (%) | |||||||
| Baseline | 123 | 2.4 | 62.4 (22.8) | 116 | 2.5 | 59.8 (20.9) | 0.372 |
| C3/C4 | 98 | 0.0 | 66.5 (22.2) | 96 | 1.0 | 62.2 (18.0) | 0.050 |
| C6/C8 | 78 | 0.0 | 64.5 (21.7) | 73 | 1.4 | 62.7 (19.0) | 0.349 |
| Final visit | 63 | 0.0 | 58.1 (22.8) | 63 | 3.1 | 60.4 (19.1) | 0.449 |
| Fatigue (%) | |||||||
| Baseline | 125 | 0.8 | 40.3 (29.1) | 117 | 1.7 | 38.4 (27.6) | 0.626 |
| C3/C4 | 98 | 0.0 | 36.9 (24.9) | 97 | 0.0 | 40.3 (26.9) | 0.510 |
| C6/C8 | 78 | 0.0 | 38.1 (27.5) | 73 | 1.4 | 40.3 (26.9) | 0.536 |
| Final visit | 63 | 0.0 | 45.1 (27.2) | 65 | 0.0 | 41.5 (25.9) | 0.475 |
| Nausea and vomiting (%) | |||||||
| Baseline | 125 | 0.8 | 6.0 (14.9) | 118 | 0.8 | 8.2 (19.5) | 0.395 |
| C3/C4 | 98 | 0.0 | 11.9 (19.6) | 97 | 0.0 | 12.2 (22.2) | 0.738 |
| C6/C8 | 78 | 0.0 | 10.5 (17.8) | 73 | 1.4 | 13.0 (21.2) | 0.687 |
| Final visit | 63 | 0.0 | 10.3 (18.3) | 65 | 0.0 | 10.3 (17.6) | 0.991 |
| Pain (%) | |||||||
| Baseline | 126 | 0.0 | 23.3 (27.8) | 118 | 0.8 | 24.0 (27.6) | 0.707 |
| C3/C4 | 98 | 0.0 | 19.0 (24.5) | 97 | 0.0 | 18.7 (23.0) | 0.949 |
| C6/C8 | 78 | 0.0 | 20.9 (28.9) | 74 | 0.0 | 17.3 (20.0) | 0.908 |
| Final visit | 63 | 0.0 | 31.2 (33.5) | 65 | 0.0 | 25.4 (26.4) | 0.512 |
| Dyspnoea (%) | |||||||
| Baseline | 123 | 1.6 | 18.0 (27.3) | 117 | 1.7 | 25.4 (28.9) | 0.017 |
| C3/C4 | 97 | 1.0 | 18.6 (25.9) | 95 | 2.1 | 18.6 (24.7) | 0.890 |
| C6/C8 | 77 | 1.3 | 18.6 (25.6) | 73 | 1.4 | 19.2 (24.8) | 0.774 |
| Final visit | 62 | 1.6 | 21.0 (27.1) | 65 | 0.0 | 20.0 (24.9) | 0.974 |
| Insomnia (%) | |||||||
| Baseline | 125 | 0.8 | 38.4 (34.1) | 117 | 1.7 | 29.1 (30.2) | 0.036 |
| C3/C4 | 98 | 0.0 | 26.5 (31.4) | 97 | 0.0 | 25.4 (29.6) | 0.916 |
| C6/C8 | 78 | 0.0 | 25.6 (31.7) | 72 | 2.7 | 20.4 (26.6) | 0.391 |
| Final visit | 63 | 0.0 | 28.6 (33.3) | 65 | 0.0 | 24.6 (27.2) | 0.725 |
| Appetite loss (%) | |||||||
| Baseline | 125 | 0.8 | 24.3 (32.9) | 116 | 2.5 | 26.1 (33.4) | 0.550 |
| C3/C4 | 98 | 0.0 | 21.4 (29.2) | 97 | 0.0 | 24.4 (34.2) | 0.798 |
| C6/C8 | 78 | 0.0 | 23.5 (30.4) | 73 | 1.4 | 19.4 (28.4) | 0.424 |
| Final visit | 62 | 1.6 | 31.2 (36.1) | 63 | 3.1 | 20.6 (30.8) | 0.106 |
| Constipation (%) | |||||||
| Baseline | 124 | 1.6 | 17.2 (29.6) | 117 | 1.7 | 18.5 (26.8) | 0.312 |
| C3/C4 | 95 | 3.1 | 13.0 (21.4) | 95 | 2.1 | 21.1 (28.8) | 0.065 |
| C6/C8 | 77 | 1.3 | 19.0 (27.3) | 73 | 1.4 | 14.6 (24.8) | 0.286 |
| Final visit | 61 | 3.2 | 22.4 (31.5) | 64 | 1.6 | 21.4 (28.1) | 0.860 |
| Diarrhoea (%) | |||||||
| Baseline | 124 | 1.6 | 16.7 (26.0) | 116 | 2.5 | 15.8 (26.2) | 0.700 |
| C3/C4 | 98 | 0.0 | 21.1 (28.1) | 96 | 1.0 | 21.2 (30.3) | 0.800 |
| C6/C8 | 77 | 1.3 | 21.2 (31.5) | 74 | 0.0 | 16.2 (25.4) | 0.506 |
| Final visit | 63 | 0.0 | 15.9 (27.3) | 64 | 1.6 | 7.8 (18.5) | 0.072 |
| Financial difficulties (%) | |||||||
| Baseline | 123 | 2.4 | 8.9 (23.4) | 114 | 4.2 | 10.8 (24.5) | 0.515 |
| C3/C4 | 98 | 0.0 | 7.1 (19.3) | 95 | 2.1 | 9.1 (20.9) | 0.477 |
| C6/C8 | 78 | 0.0 | 8.5 (21.8) | 74 | 0.0 | 11.3 (24.2) | 0.289 |
| Final visit | 63 | 0.0 | 10.1 (22.1) | 64 | 1.6 | 12.0 (22.5) | 0.479 |
Abbreviations: C3, C4, C6, C8=Cycles 3, 4, 6 and 8; EORTC=European Organisation for Research and Treatment of Cancer; %MV=percentage of missing values; QLQ-C30=Quality of Life Questionnaire-C30.
*P value: Student's t-test or Wilcoxon test for independent samples. Bold values indicate P<0.05.